C3.ai vs. UiPath: What Revenue Trends Between These Artificial Intelligence Companies Tell Investors

UiPath generated $410.3 million of revenue in the quarter ended July 31, 2026, up about 13% year over year, versus C3.ai's $52.4 million, while reporting an approximately 8% operating margin compared with C3.ai's -188%. C3.ai's revenue has fallen sharply from $108.7 million in Q1 2025 to roughly $52 million in the latest two quarters, although customer bookings rose 73% quarter over quarter following founder Thomas Siebel's June return as CEO. UiPath guided Q3 revenue to $440 million-$445 million, implying about 8% year-over-year growth and a deceleration from Q2.

Analysis

The relevant divergence is not absolute scale but operating leverage: PATH has crossed into positive operating profitability while AI’s cost base remains incompatible with its current revenue run-rate. That creates asymmetric equity sensitivity over the next 1-3 quarters: modest PATH growth deceleration can be absorbed if margins and net retention hold, whereas AI requires a sharp conversion of bookings into recognized revenue merely to reduce financing and dilution concerns. AI’s bookings figure is a leading indicator, not validation; contract duration, cancellation terms, RPO growth, and services content determine whether it becomes revenue.

Competitive dynamics favor platforms attached to measurable workflow ROI. PATH can use its installed automation footprint to bundle AI orchestration and defend renewals, while AI remains exposed to longer enterprise procurement cycles and project-based implementation risk. A slowing PATH top line could nevertheless pressure its valuation multiple if investors conclude generative AI is cannibalizing legacy RPA rather than expanding automation budgets; the key 6-18 month question is whether AI functionality lifts expansion ARR and gross margin rather than simply becoming a retention feature.

Contrarianly, the cleaner tactical opportunity may be an AI rebound only if the next report verifies bookings quality. The stock likely embeds substantial skepticism around management continuity and execution, so sequential RPO/remaining-performance-obligation acceleration plus materially narrower operating losses could drive a violent rerating. Absent those proof points, CEO dependence remains a governance discount rather than a catalyst.

Key Decisions for Investors

• Maintain a 1-3 month long PATH / short AI pair, dollar-neutral: PATH has a more credible margin floor while AI faces revenue-recognition and cash-burn risk. Target 15-20% relative outperformance; exit if PATH guides next-quarter growth below mid-single digits or AI reports RPO growth above 40% with operating-loss improvement of at least 50 percentage points.
• For PATH, wait for the next earnings print before adding directional exposure; buy only if ARR/net-retention and operating-margin guidance are maintained despite slower reported growth. Use a 10-12% stop from entry, as a guidance reset would likely trigger multiple compression disproportionate to the revenue deceleration.
• Do not buy AI solely on sequential bookings. Set an event-driven alert for disclosure of contract duration, RPO, free-cash-flow burn, and customer concentration; a long becomes actionable only if those data show bookings converting without a further deterioration in cash usage over the following 1-2 quarters.
• Avoid treating NVDA as a direct read-through: enterprise application-software execution has limited near-term linkage to accelerator demand. The more relevant sector hedge for a PATH long is short IGV or a basket of high-multiple application software if broad AI-software valuation compression resumes.